Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A retrospective single-centre cohort study identifies BMI and dyslipidemia as associations with improved PFS in anti-PD-1-treated CRC, supported by exploratory lipidomic profiling, but lacks a control arm and prospective design to establish causation or clinical utility.
This is a comprehensive narrative review synthesizing evidence on immunotherapy's current role in nasopharyngeal carcinoma management, drawing on completed and ongoing clinical trials to inform clinical practice and research priorities.
Small retrospective single-center cohort (n=13) with no comparator arm; safety and pain relief are encouraging but survival outcomes are modest and evidence requires prospective validation.
This is a bibliometric and visualization analysis of published literature on ICI cardiotoxicity, not a clinical trial or systematic review; it maps research trends and collaboration patterns but does not generate new clinical evidence or test interventions.
Preclinical evidence in a mouse model demonstrates that a sequenced triple regimen achieves high complete response rates, but findings are not yet clinically validated and lack quantitative efficacy metrics in the abstract.
Preclinical organoid-based mouse model study demonstrating proof-of-concept for CD8+ T cell dysfunction characterization and ICI responsiveness, lacking direct clinical validation or comparative efficacy trials.
This is a narrative review synthesizing existing literature on immune microenvironment characteristics and predictive models in ESCC without presenting original data or comparative efficacy evidence.